In addition, the late therapy T1D patient cohort experienced a significant decrease in daily insulin use and insulin dose-adjusted HbA1c, which could be classified as partial remission and is highly unusual in established T1D patients. This evidence concerns the gene INS and type 1 diabetes mellitus.